清髓性单倍体骨髓移植联合移植后环磷酰胺治疗儿童及成人血液系统恶性肿瘤
该单中心前瞻性2期试验纳入96例高危血液系统恶性肿瘤儿童及成人(中位年龄42岁,范围1-65岁),接受清髓性预处理后行单倍体骨髓移植联合移植后环磷酰胺。结果显示植入安全有效,1年及3年总生存率分别为73%和54%,但年龄>55岁患者非复发死亡率较高,复发与年龄增长及移植前微小残留病相关。
要点
- 中性粒细胞和血小板植入中位时间分别为24天和29天,91%患者供者细胞嵌合率>95%。
- 100天急性GVHD II-IV级和III-IV级累积发生率分别为11%和4%,6个月和12个月慢性GVHD累积发生率分别为4%和15%。
- 1年及3年总生存率分别为73%和54%,无事件生存率分别为57%和49%。
核心结论
- 清髓性预处理后行单倍体骨髓移植联合移植后环磷酰胺对成人和儿童血液系统恶性肿瘤患者安全有效。
- 年龄>55岁患者使用清髓性预处理需慎重考虑。
研究设计与样本
- 单中心前瞻性2期试验,纳入96例高危血液系统恶性肿瘤儿童或成人(中位年龄42岁,范围1-65岁),接受基于白消安或全身照射的清髓性预处理后行单倍体骨髓移植联合移植后环磷酰胺。
- 试验注册号为NCT00796562。
主要发现
- 中性粒细胞和血小板恢复中位时间分别为24天和29天,91%患者供者细胞嵌合率>95%。
- 100天急性GVHD II-IV级和III-IV级累积发生率分别为11%和4%;6个月和12个月慢性GVHD累积发生率分别为4%和15%,其中6%为中度至重度。
- 非复发死亡率100天为6%,1年为11%(年龄>55岁者为19%)。
- 1年复发累积发生率为35%,3年为43%;多变量分析显示复发与年龄增长(20-55岁P=0.02,>55岁P=0.02)及移植前微小残留病(P=0.05)相关。
- 1年和3年总生存率分别为73%和54%,无事件生存率分别为57%和49%。
临床怎么用
- 作者认为,清髓性预处理后行单倍体骨髓移植联合移植后环磷酰胺对成人和儿童血液系统恶性肿瘤患者安全有效。
- 作者指出,年龄>55岁患者使用清髓性预处理需慎重考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Promising results have been reported for patients with high-risk hematologic malignancies undergoing HLA-haploidentical bone marrow transplantation (haploBMT) with posttransplantation cyclophosphamide (PTCy), but there are few data on outcomes with myeloablative conditioning in this context. We report the results of a single-institution, prospective phase 2 trial of myeloablative haploBMT using busulfan-based or total body irradiation-based conditioning in 96 children or adults (median age, 42 years; range, 1-65 years) with high-risk hematologic malignancies. Recovery of neutrophils and platelets occurred at a median of 24 and 29 days. Engraftment of donor cells with chimerism >95% was achieved in 91%. The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and grades III to IV at day 100 was 11% and 4%, and of chronic GVHD at 6 and 12 months was 4% and 15%, with 6% moderate to severe. The cumulative incidence of nonrelapse mortality was 6% at 100 days and 11% at 1 year (19% in those aged >55 years). The cumulative incidence of relapse at 1 year was 35%; at 3 years, it was 43%. In multivariable analysis, relapse was associated with increased age (P = .02 for age 20-55 years and P = .02 for age >55 years) and with minimal residual disease before transplantation (P = .05). The overall survival at 1 and 3 years is 73% and 54%, and event-free survival at 1 and 3 years is 57% and 49%. We show that haploBMT with PTCy after myeloablative conditioning is safe and efficacious for adult and pediatric patients with hematologic malignancies. Careful consideration must be given to using myeloablative conditioning in patients age >55 years. This trial was registered at www.clinicaltrials.gov as #NCT00796562.
引用
- Symons HJ, Zahurak M, Cao Y, et al. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020. PMID: 32813874. doi:10.1182/bloodadvances.2020001648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。